NOVOMEDLINK™

This page contains information about Novo Nordisk products.

NovoLog® Mix 70/30 prescription coverage and reimbursement

More units. Same co-pay.

Covered on more than 93% of managed care plans1

One prescription of NovoLog® Mix 70/30 FlexPen® provides 50% more insulin than a vial/syringe for the same co-pay on most managed care plans.1

  • One prescription for FlexPen® (1 box of 5 pens) = 1500 units
  • One prescription for vial = 1000 units
Formulary lookup

Search the current formulary status of NovoLog® Mix 70/30 in your area to help find coverage for your patients.

Get started now

NovoLog® Mix 70/30 offers optimal access1*

Commercial plan co-pay values

For your Medicare Part D patients1

Medicare Part D co-pay values

NovoLog® Mix 70/30 FlexPen® formulary status at top commercial health care plans is comparable with that of regular human insulin.1

*Intended as a guide. Lower acquisition costs alone do not necessarily reflect a cost advantage in the outcome of the condition treated because there are other variables that affect relative costs. Formulary status is subject to change.
†Managed care plans only. Does not include Medicaid and Medicare Part D. Multiple products within the same therapeutic class may be considered preferred and on the same tier.

Related Support

Help your patients get coverage

The Novo Nordisk Patient Assistance Program (PAP) provides a lifeline for those who have difficulty affording their medications. Check patient eligibility.

Request samples

Order samples of NovoLog® Mix 70/30 FlexPen® and the NovoTwist® needle.

References:

  1. Data on file, Novo Nordisk, Inc., Princeton, NJ.

  1. NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) Indications and Usage:

    NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) is an insulin analog indicated to improve glycemic control in patients with diabetes mellitus.

    Important Limitations of Use:
    In premix insulins, such as NovoLog® Mix 70/30, the proportions of rapid acting and long acting insulins are fixed and do not allow for basal versus prandial dose adjustments.

    NovoLog® Mix 70/30 Important Safety Information:

    NovoLog® Mix 70/30 is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® Mix 70/30 or one of its excipients.

    NovoLog® Mix 70/30 has a faster onset of action than human insulin premix 70/30 and should be dosed within 15 minutes before meal initiation for patients with type 1 diabetes. For patients with type 2 diabetes, dosing should occur within 15 minutes before or after meal initiation.

    NovoLog® Mix 70/30 should not be administered intravenously or used in insulin infusion pumps. NovoLog® Mix 70/30 should not be mixed with any other insulin product.

    Hypoglycemia is the most common adverse effect of insulin therapy, including NovoLog® Mix 70/30. The timing of hypoglycemia may reflect the time-action profile of the insulin formulation. Glucose monitoring is recommended for all patients with diabetes. Any change of insulin should be made cautiously and only under medical supervision.

    Needles and NovoLog® Mix 70/30 FlexPen® must not be shared.

    Severe, life-threatening generalized allergy, including anaphylaxis, may occur with insulin products, including NovoLog® Mix 70/30. Adverse reactions observed with NovoLog® Mix 70/30 include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. Insulin, particularly when given in settings of poor glycemic control, may cause hypokalemia. Like all insulins, NovoLog® Mix 70/30 requirements may be reduced in patients with renal impairment or hepatic impairment.

    The safety and effectiveness of NovoLog® Mix 70/30 has not been established in pediatric patients. Clinical studies of NovoLog® Mix 70/30 did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger patients.

    The significance, with respect to the long-term clinical sequelae of diabetes, of the differences in postprandial hyperglycemia between treatment groups has not been established.

    Please click hereclick here for Prescribing Information.

FlexPen®, NovoLog®, and NovoTwist® are registered trademarks of Novo Nordisk A/S. NovoMedLink™ is a trademark of Novo Nordisk A/S.